| Cas No.: | 224452-66-8 |
| Chemical Name: | Acetic acid, 2-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester |
| SMILES: | O=C(CS[C@H]1C[C@@H]2CC[C@H](C1)N2C)O[C@@H]3C[C@@](C=C)([C@H]([C@@H](C4([C@@]5(C3(C)[C@@H](CC4)C)[H])CCC5=O)C)O)C |
| Formula: | C30H47NO4S |
| M.Wt: | 517.76 |
| Purity: | 99% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved For human use. It is marketed as an ointment under the brand names Altabax and Altargo. Retapamulin was approved by the United States Food and Drug Administration in April 2007 For the treatment of bacterial skin infections such as impetigo. In May 2007, retapamulin received approval in the EU from the European Medicines Agency For the same indication. For the detailed information about the solubility of Retapamulin in water, the solubility of Retapamulin in DMSO, the solubility of Retapamulin in PBS buffer, the animal experiment（test） of Retapamulin,the in vivo,in vitro and clinical trial test of Retapamulin,the cell experiment（test） of Retapamulin,the IC50, EC50 and Affinity of Retapamulin, please contact DC Chemicals. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|